mbiomics Secures €30M Series A for Microbiome Cancer Co-Therapy

Munich-based techbio company mbiomics GmbH has announced the successful completion of its Series A funding round, bringing the total capital raised to €30 million. This significant investment is earmarked to support the development of innovative microbiome-based therapeutics, with a particular focus on treating advanced melanoma.

The funding will enable mbiomics to accelerate its research and development programs, moving its promising live bacterial co-therapy closer to clinical stages. The overarching goal is to address one of the most complex challenges in modern oncology: enhancing the efficacy of current immunotherapeutic treatments.

An Innovative Approach to Melanoma Treatment

Central to mbiomics' strategy is the development of a live bacterial product. This therapy is specifically designed to boost the response to immune checkpoint inhibitors (ICIs) in patients suffering from advanced melanoma. While ICIs have revolutionized the treatment of many cancers, a significant portion of patients either do not respond or develop resistance.

Scientific research has increasingly highlighted a link between the composition of the gut microbiome and the effectiveness of immunotherapies. Alterations in the microbiome can influence the immune system's ability to recognize and combat cancer cells. mbiomics' approach aims to modulate this bacterial ecosystem to create an environment more conducive to ICI action, thereby offering new hope for patients who currently do not fully benefit from these life-saving therapies.

Next Steps and Potential Impact

With the secured capital, mbiomics plans to initiate a Phase 1B study in 2027. This clinical phase will be crucial for evaluating the safety and preliminary efficacy of the live bacterial product in combination with immune checkpoint inhibitors. Success in this phase could pave the way for larger studies and, ultimately, a new therapeutic option for advanced melanoma.

The investment in mbiomics underscores the growing interest and confidence in the potential of microbiome-based therapies. This emerging sector of biotechnology promises to unlock new strategies for tackling complex diseases, from oncology to autoimmune conditions. The ability to manipulate the microbiome to improve responses to existing treatments represents a research area with significant potential impact on human health.

mbiomics' Vision for the Future of Oncology

mbiomics positions itself at the forefront of techbio research, with a clear vision of how the microbiome can be leveraged to improve clinical outcomes in oncology. The company is committed to translating scientific discoveries into concrete therapeutic solutions, offering patients new treatment opportunities.

The Series A funding not only provides the necessary resources to advance towards clinical trials but also validates mbiomics' scientific approach and market potential. With the Phase 1B study on the horizon, the company is poised to make significant strides in its journey to bring innovation to the field of oncology co-therapies.